Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes
| Autor: | M Christodoulakis, D. Mavroudis, Stelios Kakolyris, Konstantinos Kalbakis, Lambros Vamvakas, John Souglakos, Kostas Stylianou, Ch. Kouroussis, Sophia Agelaki, V. Georgoulias |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Bridged-Ring Compounds Cancer Research medicine.medical_specialty Adolescent Maximum Tolerated Dose Anthracycline Cyclophosphamide medicine.medical_treatment Leucovorin salvage chemotherapy Salvage therapy Breast Neoplasms Gastroenterology breast cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Anthracyclines 5-fluorouracil Neoplasm Metastasis Infusions Intravenous Survival rate Aged Salvage Therapy anthracycline/taxane resistance Chemotherapy Performance status business.industry Regular Article Middle Aged medicine.disease Surgery Survival Rate Treatment Outcome Oncology Drug Resistance Neoplasm Female Taxoids Fluorouracil business Febrile neutropenia Progressive disease medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1054/bjoc.2001.2001 |
| Popis: | The purpose of this study was to evaluate the activity and tolerance of high-dose leucovorin (LV) and infusional 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) as salvage chemotherapy in patients with metastatic breast cancer (MBC) pretreated with anthracyclines and taxanes. 41 patients (median age 59 years) with MBC refractory or resistant to anthracyclines and taxanes were enrolled. The patients' performance status (WHO) was 0 in 10 patients (24%), 1 in 22 (54%), and 2 in 9 (22%). 30 (73%) patients had received 2 or more prior chemotherapy regimens. Cyclophosphamide (600 mg m−2) was given i.v. bolus on day 1 and LV (500 mg m−2 d−1) as a 2-h infusion followed by 5-FU (1.5 g m−2 d−1) over a 22 h c.i. for 2 consecutive days. Cyclophosphamide was administered every 28 days while 5-FU/LV every 14 days. In an intention-to-treat analysis, complete response (CR) was achieved in 2 (4.9%) patients and partial response (PR) in 9 (22%) (overall response rate 26.9%; 95% CI: 13.27–40.39%). Stable disease (SD) and progressive disease (PD) were observed in 9 (22%) and 21 (51%) patients, respectively. The overall response rate was 6% and 40% in patients with primary and secondary resistance to anthracyclines/taxanes, respectively (P = 0.047). The median duration of response and the median time to disease progression was 8 and 9.5 months, respectively. The median overall survival was 13 months and the probability for 1-year survival 51%. Grade 3/4 neutropenia occurred in 9 (22%) patients and 4 (9%) patients developed grade 3/4 thrombocytopenia. Non-haematological toxicity was mild. There were no cases of febrile neutropenia, toxic deaths or treatment-related hospital admissions due to toxicity. The combination of high-dose 5-FU/LV with conventional doses of cyclophosphamide is a well tolerated and effective salvage regimen in patients with MBC heavily pretreated with both anthracyclines and taxanes. © 2001 Cancer Research Campaignhttp://www.bjcancer.comhttp://www.bjcancer.com |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|